• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Daily Derm Times: March 12, 2025

Key Takeaways

  • Ruxolitinib cream shows lasting safety and efficacy in children with moderate to severe atopic dermatitis.
  • Dupilumab therapy results in a 70% reduction in IgE levels in young children with moderate-to-severe atopic dermatitis.
SHOW MORE

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times logo

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Journal Digest: March 12

This review of the latest dermatologic studies includes insights into erectile dysfunction in dermatology and venereology, diet and psoriasis information on TikTok, and more.

Ruxolitinib Cream Shows Lasting Results in Pediatric Max-Use Trial

Ruxolitinib cream showlasting safety and efficacy in children with moderate to severe atopic dermatitis.

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Robert Bissonnette, MD: Late-Breaking Data on Icotrokinra Shows Promising Efficacy and Safety in Psoriasis

Bissonnette shared highlights and insights on the icotrokinra data presented at the AAD Annual Meeting.

Empowering the Eczema Community: NEA’s Vision for Support, Education, and Awareness

Renata Block, MMS, PA-C, speaks with Wendy Smith Begolka, MBS, of the National Eczema Association about NEA’s strategic efforts in community outreach, health care provider engagement, and patient education.

The Rx Recap: March 2-8

This week, we feature top articles from our sister publications on updates in surgical management, diabetes control, and more.

VYC-17.5L Can Be Used for Safe and Effective Contouring on the Forehead

Nearly all patients in a new study saw an improved appearance in their forehead up to 12 months after treatment.

Bridging the Gap Between Patient Experience and Clinical Definitions in Eczema

Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C, discuss redefining eczema flares to align clinical and patient perspectives.

FDA Alerts of New Independent Testing for Benzoyl Peroxide Acne Products, Additional Voluntary Recalls

The agency shared details of additional voluntary recalls and its plans to release full results of its independent testing in the coming months.

Related Videos
© 2025 MJH Life Sciences

All rights reserved.